Free Trial

TuHURA Biosciences (HURA) Competitors

$3.40 +0.11 (+3.34%)
(As of 02:30 PM ET)

HURA vs. FBRX, MIRA, PIRS, CYTH, GLYC, SPRB, UBX, MEIP, FNCH, and PRPH

Should you be buying TuHURA Biosciences stock or one of its competitors? The main competitors of TuHURA Biosciences include Forte Biosciences (FBRX), MIRA Pharmaceuticals (MIRA), Pieris Pharmaceuticals (PIRS), Cyclo Therapeutics (CYTH), GlycoMimetics (GLYC), Spruce Biosciences (SPRB), Unity Biotechnology (UBX), MEI Pharma (MEIP), Finch Therapeutics Group (FNCH), and ProPhase Labs (PRPH). These companies are all part of the "pharmaceutical products" industry.

TuHURA Biosciences vs.

Forte Biosciences (NASDAQ:FBRX) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, institutional ownership, earnings and analyst recommendations.

Forte Biosciences has a beta of 0.04, indicating that its share price is 96% less volatile than the S&P 500. Comparatively, TuHURA Biosciences has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.

77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are held by institutional investors. 9.6% of Forte Biosciences shares are held by insiders. Comparatively, 0.2% of TuHURA Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Forte Biosciences had 11 more articles in the media than TuHURA Biosciences. MarketBeat recorded 12 mentions for Forte Biosciences and 1 mentions for TuHURA Biosciences. Forte Biosciences' average media sentiment score of 0.72 beat TuHURA Biosciences' score of -3.00 indicating that Forte Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Forte Biosciences Positive
TuHURA Biosciences Very Negative

Forte Biosciences received 28 more outperform votes than TuHURA Biosciences when rated by MarketBeat users.

CompanyUnderperformOutperform
Forte BiosciencesOutperform Votes
28
59.57%
Underperform Votes
19
40.43%
TuHURA BiosciencesN/AN/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Forte BiosciencesN/AN/A-$31.48M-$16.29-0.90
TuHURA BiosciencesN/AN/A-$8.32MN/AN/A

Forte Biosciences presently has a consensus target price of $23.58, indicating a potential upside of 60.43%. TuHURA Biosciences has a consensus target price of $15.00, indicating a potential upside of 341.18%. Given TuHURA Biosciences' higher possible upside, analysts plainly believe TuHURA Biosciences is more favorable than Forte Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Forte Biosciences
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
TuHURA Biosciences
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

TuHURA Biosciences' return on equity of 0.00% beat Forte Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Forte BiosciencesN/A -151.43% -118.92%
TuHURA Biosciences N/A N/A -152.88%

Summary

Forte Biosciences beats TuHURA Biosciences on 7 of the 11 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HURA vs. The Competition

MetricTuHURA BiosciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$4.90M$6.49B$5.07B$8.90B
Dividend YieldN/A8.11%4.99%4.07%
P/E RatioN/A4.8587.8613.46
Price / SalesN/A374.821,228.8287.66
Price / CashN/A52.5939.5136.27
Price / Book3.4610.216.946.30
Net Income-$8.32M$153.61M$119.12M$225.93M
7 Day Performance-37.14%-2.00%-1.84%-1.32%
1 Month PerformanceN/A-7.47%-3.65%0.60%
1 Year PerformanceN/A31.80%31.64%26.23%

TuHURA Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HURA
TuHURA Biosciences
0.9691 of 5 stars
$3.40
+3.3%
$15.00
+341.2%
N/A$5.41MN/A0.00N/ANegative News
Gap Up
FBRX
Forte Biosciences
3.6486 of 5 stars
$14.70
+8.5%
$23.58
+60.4%
+69,372.9%$21.46MN/A-0.685Analyst Revision
News Coverage
Gap Down
High Trading Volume
MIRA
MIRA Pharmaceuticals
1.6713 of 5 stars
$1.27
+0.4%
$14.00
+1,002.4%
-72.8%$21.03MN/A0.002
PIRS
Pieris Pharmaceuticals
1.6396 of 5 stars
$15.93
-0.5%
N/A-10.4%$21.03M$42.81M-1.32140Analyst Upgrade
News Coverage
Gap Down
CYTH
Cyclo Therapeutics
2.7701 of 5 stars
$0.70
-1.3%
$0.95
+35.7%
-47.9%$20.14M$1.08M0.009News Coverage
Gap Down
GLYC
GlycoMimetics
3.442 of 5 stars
$0.31
-6.1%
$10.00
+3,125.8%
-78.4%$19.99M$10,000.000.0050Gap Down
SPRB
Spruce Biosciences
2.9764 of 5 stars
$0.48
-1.7%
$4.00
+730.2%
-64.0%$19.90M$10.09M0.0020Gap Down
UBX
Unity Biotechnology
3.6114 of 5 stars
$1.15
-1.4%
$8.00
+593.4%
-42.1%$19.44M$240,000.000.0060
MEIP
MEI Pharma
4.2134 of 5 stars
$2.84
+1.4%
$7.00
+146.5%
-50.5%$18.91M$65.30M-0.40100
FNCH
Finch Therapeutics Group
N/A$11.45
flat
N/A+216.3%$18.43M$110,000.000.00190
PRPH
ProPhase Labs
3.2606 of 5 stars
$0.77
+0.5%
$11.00
+1,331.2%
-82.8%$18.35M$44.38M0.00130High Trading Volume

Related Companies and Tools


This page (NASDAQ:HURA) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners